Drug Trial Radar · NCT05975073
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Aug 1, 2023
Primary completion
Feb 25, 2026
Study completion Mar 26, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of anvumetostat in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Conditions
- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors
Interventions
AnvumetostatDrug
Administered PO
IDE397Drug
Administered PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)Time frame: Day 1 up to Day 21
- Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 up to approximately 2.5 years
- Part 1: Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Day 1 up to approximately 2.5 years
- Part 2: Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Day 1 up to approximately 2.5 years
Locations
27 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Sarah Cannon Research Institute
Denver, Colorado
Community Health Network MD Anderson Cancer Center - North
Indianapolis, Indiana
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Health Partners Cancer Center at Regions Hospital
Saint Paul, Minnesota
Astera Cancer Care
East Brunswick, New Jersey
New York University Grossman School of Medicine and New York University Langone Hospitals
New York, New York
Columbia University Irving Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University
Durham, North Carolina
Prisma Health Upstate
Greenville, South Carolina
University of Texas MD Anderson Cancer Center
Houston, Texas
Next Oncology
Irving, Texas
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Rigshospitalet
Copenhagen, Denmark
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.